Diabetes Mellitus in Chronic Pancreatitis

Diabetes secondary to pancreatic diseases is commonly referred to as pancreatogenic diabetes or type 3c diabetes mellitus. It is a clinically relevant condition with a prevalence of 5-10% among all diabetic subjects in Western populations. In nearly 80% of all type 3c diabetes mellitus cases, chronic pancreatitis seems to be the underlying disease. The prevalence and clinical importance of diabetes secondary to chronic pancreatitis has certainly been underestimated and underappreciated so far. In contrast to the management of type 1 or type 2 diabetes mellitus, the endocrinopathy in type 3c is very complex. The course of the disease is complicated by additional present comorbidities such as maldigestion and concomitant qualitative malnutrition. General awareness that patients with known and/or clinically overt chronic pancreatitis will develop type 3c diabetes mellitus (up to 90% of all cases) is rather good. However, in a patient first presenting with diabetes mellitus, chronic pancreatitis as a potential causative condition is seldom considered. Thus many patients are misdiagnosed. The failure to correctly diagnose type 3 diabetes mellitus leads to a failure to implement an appropriate medical therapy. In patients with type 3c diabetes mellitus treating exocrine pancreatic insufficiency, preventing or treating a lack of fat-soluble vitamins (especially vitamin D) and restoring impaired fat hydrolysis and incretin secretion are key-features of medical therapy.

Download Full-text

Impaired response of human pancreatic polypeptide to insulin-induced hypoglycemia in chronic pancreatitis without diabetes mellitus.

Endocrinologia Japonica ◽

10.1507/endocrj1954.29.509 ◽

1982 ◽

Vol 29 (5) ◽

pp. 509-515 ◽

Cited By ~ 3

Author(s):

TOSHIAKI HANAFUSA ◽

HIROYUKI TOYOSHIMA ◽

KYOHEI NONAKA ◽

SEIICHIRO TARUI

Keyword(s):

Diabetes Mellitus ◽

Chronic Pancreatitis ◽

Pancreatic Polypeptide ◽

Human Pancreatic Polypeptide

Download Full-text

Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus

Pancreas ◽

10.1097/mpa.0000000000001077 ◽

2018 ◽

pp. 1 ◽

Cited By ~ 2

Author(s):

Sajan Jiv Singh Nagpal ◽

William R. Bamlet ◽

Yogish C. Kudva ◽

Suresh T. Chari

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chronic Pancreatitis ◽

Pancreatic Ductal Adenocarcinoma ◽

Pancreatic Polypeptide ◽

Ductal Adenocarcinoma ◽

Human Pancreatic Polypeptide

Download Full-text

Exocrine and endocrine functions of the pancreas in the diabetes mellitus and chronic pancreatitis

Gastroenterologia Japonica ◽

10.1007/bf02780113 ◽

1969 ◽

Vol 4 (2) ◽

pp. 141-141

Author(s):

S. Yamagata ◽

Y. Goto ◽

T. Takebe ◽

H. Koizumi ◽

M. Ohomiya

Keyword(s):

Diabetes Mellitus ◽

Chronic Pancreatitis

Download Full-text

EVALUATION OF PARAMETERS OF ACTUAL TYPICAL PATHOGENETIC SYNDROMES IN COMORBIDITY OF TYPE 2 DIABETES MELLITUS AND CHRONIC PANCREATITIS

Wiadomości Lekarskie ◽

10.36740/wlek202110204 ◽

2021 ◽

Vol 74 (10) ◽

pp. 2557-2559

Author(s):

Olena V. Redkva ◽

Liliya S. Babinets ◽

Iryna M. Halabitska

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chronic Pancreatitis ◽

Antioxidant Protection ◽

Enzymatic Antioxidant ◽

Evaluation Of Parameters ◽

Remission Phase ◽

The Impact

The aim: To assess the state of typical pathogenetic syndromes (inflammation, endotoxicosis, liperoxidation, enzymatic and non-enzymatic antioxidant deficiency) in the comorbidity of type 2 diabetes mellitus (DM2) and chronic pancreatitis (CP). Materials and methods: We examined 137 patients (112 patients with comorbidity of CP and DM2 and 25 patients with isolated CP. Typical pathogenetic syndromes (inflammation, endotoxicosis, liperoxidation, enzymatic and non-enzymatic antioxidant deficiency) were determined. Results: It was proved that patients with CP even in the remission phase of the active course of EI and LPO, which was significantly more significant in comorbidity with DM2. Statistically significant more significant changes in the parameters of antioxidant protection in the comorbidity of CP and DM2 in relation to those in isolated CP. Conclusions: Treatment of CP and DM2 is a difficult task and should take into account the impact on the studied common typical pathogenetic syndromes – inflammation, endotoxicosis, lipid peroxidation, and enzyme and non-enzymatic antioxidant protection – to address short-term and prevent long-term complications.

Download Full-text